RxDoctor Payments Data

Sean Brady, MD

Allergy & Immunology · Williamsville, NYNPI 1356583124

Payments from drug & device makers

$4,679in general payments, 2019–2025

Across 103 payments — averaging $45.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$831
  • Sanofi$625
  • CSL Behring$418
  • Genentech USA, Inc.$381
  • Pfizer$248
  • plus $1K from 9 others

What the payments were for

  • Food & beverage$4,679100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,679 in reported general payments places this provider in the 55th percentile of 320 allergy & immunology providers in New York.

See all allergy & immunology providers in New York

Medicare billing

Part B allowed, 2024
$15,920
Medicare patients
85
Services billed
401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FirazyrIcatibant Acetate28$11,354,653
BerinertC1 Esterase Inhibitor23$6,437,783
TakhzyroLanadelumab-Flyo15$1,039,648
Dupixent PenDupilumab98$397,348
XolairOmalizumab103$308,785
NucalaMepolizumab48$185,910
Dupixent SyringeDupilumab28$103,234
HizentraImmun Glob G(Igg)/Pro/Iga 0-5013$96,887
HyqviaIgg/Hyaluronidase,recombinant12$82,590
Fasenra PenBenralizumab12$62,433
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$42,286
Advair HfaFluticasone Propion/Salmeterol66$33,992
Breo ElliptaFluticasone/Vilanterol35$27,196
Cromolyn Sodium29$12,117
SymbicortBudesonide/Formoterol Fumarate38$10,131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Firazyr, Takhzyro, Hyqvia$125$12,476,89155 claims
CSL BehringBerinert, Hizentra$418$6,534,67036 claims
Genentech, Inc.Xolair$36$308,785103 claims
GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta$1,038$260,921144 claims
AstraZenecaSymbicort$831$10,13138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 320 allergy & immunology providers in New York.

Other allergy & immunology in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →